Disease-modifying antirheumatic drug (DMARD) reverses the hypomethylation of RNF5 and AGPAT1 promoter regions induced by smoking in patients with RA; therefore, it could be considered as a therapeutic target for RA (Svendsen et al., 2016). This evidence concerns the gene RNF5 and rheumatoid arthritis.